Evidence map›Paper›PMID 19548124›Full record

ArticleClinical reviews in allergy & immunology2010

Efficacy and safety of anti-tumour necrosis factor in elderly patients with rheumatoid arthritis: an observational study.

Matteo Filippini, Chiara Bazzani, Ennio Giulio Favalli, Antonio Marchesoni, Fabiola Atzeni, Piercarlo Sarzi-Puttini, Francesca Bobbio Pallavicini, Roberto Caporali, Roberto Gorla

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical reviews in allergy & immunology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
3.0field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 74 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Observational
  9. Observational
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Observational
  16. Review
  17. Article
  18. Review
  19. Elderly patients and inflammatory bowel disease.World journal of gastrointestinal pharmacology and therapeutics · 2016
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Matteo FilippiniRheumatology and Immunology Unit, Spedali Civili di Brescia, 25123 Brescia, Italy. filippini@bresciareumatologia.it
Chiara Bazzani
Ennio Giulio Favalli
Antonio Marchesoni
Fabiola Atzeni
Piercarlo Sarzi-Puttini
Francesca Bobbio Pallavicini
Roberto Caporali
Roberto Gorla
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia · ITLuigi Sacco Hospital · ITOrthopedic Institute · USIstituti di Ricovero e Cura a Carattere Scientifico · ITPoliclinico San Matteo Fondazione · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aims to compare the efficacy and safety of anti-TNF agents in elderly (aged >or=65 years) and younger patients (aged 18-65 years) with active RA. The study involved 1,114 RA patients treated with anti-TNF drugs and followed-up for >6 months by LORHEN group, who were divided into two cohorts on the basis of their age (311 aged >or=65 and 803 aged <65 years) in order to evaluate 3-year outcomes and treatment discontinuations. Drug effectiveness was assessed by disease activity (DAS28 and EULAR response), functional status (HAQ) and serological parameters (ESR) at baseline and during anti-TNFalpha therapy; safety was evaluated on the basis of drug discontinuation rates. At baseline, the elderly patients showed greater disease activity (DAS28, ESR) and loss of joint function (HAQ, functional class; p < 0.05). During therapy, clinical and laboratory parameters (DAS28, ESR) improved in both groups without any statistically significant difference between them, whereas the difference in HAQ remained after 36 months of treatment (p < 0.05). Anti-TNFalpha therapy was discontinued by 123 of the elderly (42%) and 282 of the younger patients (36.6%) because of loss of efficacy (17.4% vs. 16.7%), severe adverse events (21.8% vs. 16.9%) or other reasons (2.7% vs. 3%). The number of adverse events was significantly higher in the elderly patients (p < 0.05). Anti-TNFalpha treatment reduced disease activity and led to functional improvement in both groups, although the baseline difference in HAQ remained statistically significant at the end of the follow-up. The elderly patients experienced more infective events.

Indexed as

AdolescentAdultAgedAntirheumatic AgentsArthritis, RheumatoidFemaleHumansMaleMiddle AgedRecovery of FunctionTreatment OutcomeTumor Necrosis Factor-alphaYoung AdultAntirheumatic AgentsTumor Necrosis Factor-alpha

Identifiers

PMID19548124
OpenAlexW2022205836

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.